Healthcare | November 25, 2021
Fedo partners with Open to launch `Health Savings Account’
A first for the Asian market, addressing the health spends needs of over 200 million households.
A first for the Asian market, addressing the health spends needs of over 200 million households.
Featuring identity verification using artificial intelligence (AI), LabPort was designed to facilitate immediate results reporting for diagnostic testing even in high-volume, field-based testing environments
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
Obseva announced previously that the company has entered into a partnership with Syneos Health to support commercialization of linzagolix in the US and EU
.jpg)
Molbio Diagnostics has been the pioneer in providing access to molecular testing through its Truenat Real Time PCR platform. Sriram Natarajan, Director & CEO, of the company shares his experiences on the journey so far in an interview with Thomas C Thottathil
Five potential first-in-class assets aimed at delivering significant long-term growth. Over 14 clinical development programs underway across portfolio and 11 new studies to start in 2022 across early- and late-stage pipeline
The industry is at an inflection point and it awaits mega investments, the right government policies, and the creation of a strong ecosystem to propel innovation
Flipkart also announced its foray into the healthcare sector through the launch of Flipkart Health+
The final data from the trial showed sotrovimab reduces hospitalisation and risk of death by 79% in adults with mild-to-moderate Covid-19 who are at high risk of progression to severe disease
Nelarabine is in a class of medications called antimetabolites
Subscribe To Our Newsletter & Stay Updated
